Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
BRILINTA | AstraZeneca | N-022433 RX | 2011-07-20 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
brilinta | New Drug Application | 2024-11-04 |
ticagrelor | ANDA | 2025-05-07 |
Expiration | Code | ||
---|---|---|---|
TICAGRELOR, BRILINTA, ASTRAZENECA | |||
2025-11-09 | PED | ||
2025-05-09 | M-283 | ||
2024-05-05 | PED | ||
2023-11-05 | I-848 |
Code | Description |
---|---|
G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 2 | 6 | 10 | 16 | 34 |
Coronary artery disease | D003324 | — | I25.1 | 1 | 5 | 7 | 15 | 1 | 28 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 4 | 6 | 8 | 19 |
Infarction | D007238 | EFO_0009463 | — | — | 1 | 3 | 5 | 8 | 17 |
Syndrome | D013577 | — | — | — | 1 | 3 | 7 | 6 | 17 |
Coronary disease | D003327 | — | — | — | 4 | 2 | 9 | 1 | 16 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 5 | 3 | 9 | — | 16 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 2 | 5 | 1 | 8 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | 5 | 1 | 7 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | 2 | 2 | 1 | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | 2 | 2 | — | — | 6 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 4 | — | — | 4 |
Stable angina | D060050 | — | I20.89 | — | — | 2 | — | — | 2 |
Ischemic stroke | D000083242 | — | — | — | — | 2 | — | — | 2 |
Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | — | 2 | — | — | 2 |
Percutaneous coronary intervention | D062645 | — | — | — | — | 1 | — | — | 1 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | — | 1 |
Death | D003643 | PATO_0001422 | — | — | — | 1 | — | — | 1 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | 1 | — | — | 1 |
Intracranial arteriosclerosis | D002537 | EFO_1000860 | I67.2 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 2 | 1 | — | — | — | 2 |
Dyspnea | D004417 | — | R06.0 | — | 1 | — | — | 1 | 2 |
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | — | — | 1 |
Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | — | — | — | 1 |
Obstructive lung diseases | D008173 | — | — | — | 1 | — | — | — | 1 |
Arteriovenous fistula | D001164 | — | Q27.3 | 1 | 1 | — | — | — | 1 |
Fistula | D005402 | — | — | 1 | 1 | — | — | — | 1 |
Vascular patency | D014654 | — | — | 1 | 1 | — | — | — | 1 |
Abdominal aortic aneurysm | D017544 | EFO_0004214 | — | — | 1 | — | — | — | 1 |
Aneurysm | D000783 | — | I72.9 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
Renal insufficiency | D051437 | — | N19 | 2 | — | — | — | — | 2 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
Blood flow velocity | D001783 | — | — | 1 | — | — | — | — | 1 |
Coronary circulation | D003326 | — | — | 1 | — | — | — | — | 1 |
Gout | D006073 | EFO_0004274 | M10 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | — | — | 2 | 2 |
Acute kidney injury | D058186 | — | N17 | — | — | — | — | 1 | 1 |
Liver failure | D017093 | — | K72.9 | — | — | — | — | 1 | 1 |
Acute liver failure | D017114 | — | — | — | — | — | — | 1 | 1 |
Coma | D003128 | — | R40.2 | — | — | — | — | 1 | 1 |
Drug common name | Ticagrelor |
INN | ticagrelor |
Description | Ticagrelor is a triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome. It has a role as a platelet aggregation inhibitor and a P2Y12 receptor antagonist. It is a member of triazolopyrimidines, an organofluorine compound, an aryl sulfide, a secondary amino compound and a hydroxyether. |
Classification | Small molecule |
Drug class | platelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1 |
PDB | — |
CAS-ID | 274693-27-5 |
RxCUI | — |
ChEMBL ID | CHEMBL398435 |
ChEBI ID | 68558 |
PubChem CID | 9871419 |
DrugBank | DB08816 |
UNII ID | GLH0314RVC (ChemIDplus, GSRS) |